
Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – HC Wainwright lifted their Q4 2026 EPS estimates for Sutro Biopharma in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($1.93) per share for the quarter, up from their previous estimate of ($2.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($8.08) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q3 2027 earnings at ($2.41) EPS, Q4 2027 earnings at ($2.67) EPS, FY2027 earnings at ($9.24) EPS, FY2028 earnings at ($10.87) EPS, FY2029 earnings at ($7.59) EPS and FY2030 earnings at ($7.83) EPS.
Several other research firms also recently weighed in on STRO. Wall Street Zen raised Sutro Biopharma from a “strong sell” rating to a “sell” rating in a research note on Monday. Wedbush reiterated an “outperform” rating and set a $60.00 target price on shares of Sutro Biopharma in a research report on Thursday, October 15th. Wells Fargo & Company began coverage on Sutro Biopharma in a research report on Wednesday, September 30th. They set an “overweight” rating and a $49.00 target price on the stock. Citizens Jmp lowered their target price on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Finally, Stifel Nicolaus set a $48.00 price target on Sutro Biopharma and gave the company a “buy” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sutro Biopharma has an average rating of “Buy” and a consensus target price of $49.60.
Sutro Biopharma Price Performance
Shares of NASDAQ:STRO opened at $8.50 on Tuesday. The firm has a market capitalization of $141.10 million, a price-to-earnings ratio of -1.19 and a beta of 1.56. The business’s 50 day simple moving average is $12.56 and its 200-day simple moving average is $22.45. Sutro Biopharma has a 12 month low of $7.15 and a 12 month high of $43.85.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.26). The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $14.11 million.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC lifted its stake in Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in Sutro Biopharma during the 1st quarter valued at $19,956,000. Perceptive Advisors LLC purchased a new position in Sutro Biopharma during the first quarter worth $17,818,000. ADAR1 Capital Management LLC increased its position in Sutro Biopharma by 681.8% during the first quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after buying an additional 457,364 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new position in shares of Sutro Biopharma in the second quarter worth $9,042,053. 96.99% of the stock is currently owned by institutional investors and hedge funds.
Sutro Biopharma Company Profile
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
Recommended Stories
- Five stocks we like better than Sutro Biopharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
